Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MOREErbB-2, also known as human epidermal growth factor receptor 2 (HER2), cluster of differentiation 340 (CD340), proto-oncogene Neu, is encoded by the ERBB2 gene. As a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family, ErbB2 has become an important biomarker and target of therapy for breast cancer. Not only the overexpression of ErbB2 occurs in breast cancer, but also it is strongly associated with the ovarian cancer, stomach cancer, lung adenocarcinoma, uterine cancer, salivary gland cancer, acute lymphoblastic leukemia (ALL), bladder cancer, childhood medulloblastoma, colorectal cancer, oral squamous cell carcinoma, germ-cell testicular tumor, cholangiocarcinoma, osteosarcoma, pancreatic adenocarcinoma and prostate cancer.
Associated Disease
Loading...| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
| CAR-T-1-L337-2 | Anti-ErbB2 scFv h(CD28) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28 | Lentiviral | T cell | |
| CAR-T-1-L337-G | Anti-ErbB2 scFv h(FcεRIγ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-FcεRIγ | Lentiviral | T cell | |
| CAR-T-1-L337-Z | Anti-ErbB2 scFv h(CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-L337-2G | Anti-ErbB2 scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-FcεRIγ | Lentiviral | T cell | |
| CAR-T-2-L337-2Z | Anti-ErbB2 scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-L337-4G | Anti-ErbB2 scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD4-FcεRIγ | Lentiviral | T cell | |
| CAR-T-2-L337-4Z | Anti-ErbB2 scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD4-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-L337-8Z | Anti-ErbB2 scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD8-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-L337-BZ | Anti-ErbB2 scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-L337-CZ | Anti-ErbB2 scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-b2c-CD3ζ | Lentiviral | T cell | |
| CAR-T-3-L337-2BZ | Anti-ErbB2 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M550-BZ | Anti-HER2 VHH h(41BB-CD3ζ) CAR, [T] | Human | Camelid | VHH-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M550-CZ | Anti-HER2 VHH h(b2c-CD3ζ) CAR, [T] | Human | Camelid | VHH-b2c-CD3ζ | Lentiviral | T cell | ||
| CAR-T-1-M550-2 | Anti-HER2 VHH h(CD28) CAR, [T] | Human | Camelid | VHH-CD28 | Lentiviral | T cell | ||
| CAR-T-3-M550-2BZ | Anti-HER2 VHH h(CD28-41BB-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD28-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M550-2Z | Anti-HER2 VHH h(CD28-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD28-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M550-2G | Anti-HER2 VHH h(CD28-FcεRIγ) CAR, [T] | Human | Camelid | VHH-CD28-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-3-M550-2XZ | Anti-HER2 VHH h(CD28-OX40-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD28-OX40-CD3ζ | Lentiviral | T cell | ||
| CAR-T-1-M550-Z | Anti-HER2 VHH h(CD3ζ) CAR, [T] | Human | Camelid | VHH-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M550-4Z | Anti-HER2 VHH h(CD4-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD4-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M550-4G | Anti-HER2 VHH h(CD4-FcεRIγ) CAR, [T] | Human | Camelid | VHH-CD4-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-2-M550-8Z | Anti-HER2 VHH h(CD8-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD8-CD3ζ | Lentiviral | T cell | ||
| CAR-T-1-M550-G | Anti-HER2 VHH h(FcεRIγ) CAR, [T] | Human | Camelid | VHH-FcεRIγ | Lentiviral | T cell | ||
| CAR-MZ132 | Anti-ErbB2 (L96) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | L96 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | |
| CAR-MZ133 | Anti-ErbB2 (N29) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | N29 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | |
| CAR-MZ134 | Anti-ErbB2 (4D5 ) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 4D5 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | |
| CAR-MZ135 | Anti-ErbB2 (L96) h(CD28-FcγR) CAR, pCDCAR1 | Human | L96 | Mouse | scFv-CD28-FcγR | Retroviral | T cell | |
| CAR-MZ136 | Anti-ErbB2 (N29) h(CD28-FcγR) CAR, pCDCAR1 | Human | N29 | Mouse | scFv-CD28-FcγR | Retroviral | T cell | |
| CAR-MZ019 | Anti-ErbB2 (Trastuzumab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Trastuzumab | Humanized | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-MZ029 | Anti-ErbB2 (C6-B1D2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6-B1D2 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-MZ030 | Anti-ErbB2 (C6MH3-B1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6MH3-B1 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-MZ137 | Anti-ErbB2 (4D5 ) h(CD28-FcγR) CAR, pCDCAR1 | Human | 4D5 | Mouse | scFv-CD28-FcγR | Retroviral | T cell | |
| CAR-MZ031 | Anti-ErbB2 (C6ML3-9) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6ML3-9 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-MZ032 | Anti-ErbB2 (C6.5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6.5 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-MZ033 | Anti-ErbB2 (C6.5G98A) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6.5G98A | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-T-3-L337-2XZ | Anti-ErbB2 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | |
| CAR-NK-1-M331-2 | Anti-ErbB2 scFv h(CD28) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD28 | Lentiviral | NK cell | |
| CAR-NK-1-M331-G | Anti-ErbB2 scFv h(FcεRIγ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-FcεRIγ | Lentiviral | NK cell | |
| CAR-NK-1-M331-Z | Anti-ErbB2 scFv h(CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-2-M331-2Z | Anti-ErbB2 scFv h(CD28-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD28-CD3ζ | Lentiviral | NK cell |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
